Reported Friday, AstraZeneca And Daiichi Sankyo's ENHERTU Wins FDA Approval In Neoadjuvant And Adjuvant HER2-Positive Early Breast Cancer

AstraZeneca PLC
DAIICHI SANKYO COMPANY LIMITED

AstraZeneca PLC

AZN

0.00

DAIICHI SANKYO COMPANY LIMITED

DSNKY

0.00

Approved for use before surgery based on DESTINY-Breast11 Phase III trial

Approved for use following surgery based on DESTINY-Breast05 Phase III trial

Two new indications bring AstraZeneca and Daiichi Sankyo's ENHERTU into curative-intent setting, reinforcing its role across stages of HER2-positive breast cancer

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.